Utah Doc Banned from Prescribing Pills After License Surrender
Published Date: 7/22/2025
Notice
Summary
Dr. Thomas Draschil from Utah lost his DEA registration because he gave up his state medical and controlled substance licenses last year. Since he didn’t ask for a hearing, the DEA officially canceled his right to handle controlled substances starting July 22, 2025. This means he can no longer legally prescribe or manage controlled drugs, affecting his medical practice and any related income.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
DEA Registration Revoked for Dr. Draschil
Dr. Thomas Draschil's DEA Certificate of Registration No. FD9980118 is revoked and the Order is effective August 21, 2025. Because his Utah physician license and Utah controlled-substance license were voluntarily surrendered on July 29, 2024, he is not authorized to handle, prescribe, dispense, or administer controlled substances in Utah.
Pending Renewal and New Registrations Denied
The DEA denied any pending applications by Thomas Draschil to renew or modify his registration and denied any pending application for additional registration in Utah, with that denial effective August 21, 2025. The Order follows findings that he is not licensed as a practitioner in Utah.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-11572 — Ashley Vermillion, N.P.; Decision and Order
Ashley Vermillion, a nurse practitioner from Maine, lost her DEA registration because she no longer has the legal right to handle controlled substances in her state. She didn’t ask for a hearing, so the DEA moved forward and officially revoked her registration. This means she can’t prescribe or manage controlled drugs anymore, effective immediately.
2026-11416 — Importer of Controlled Substances Application: CalCog Inc.
CalCog Inc. wants to become an official importer of some powerful controlled substances like LSD and 5-MeO-DMT. People and companies involved with these drugs have until July 8, 2026, to share their thoughts or ask for a hearing. This move could shake up the import scene, but no costs or changes happen until the DEA decides.
2026-10380 — Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
The DEA wants to put diphenidine, a drug, into Schedule I, which means it will be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or owns diphenidine, adding strict rules and penalties. You’ve got until June 25, 2026, to share your thoughts before the new rules might kick in.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
Previous / Next Documents
Previous: 2025-13712 — Notice of Request for Revision to and Extension of Approval of an Information Collection; Federal Plant Pest and Noxious Weed Regulations
The Animal and Plant Health Inspection Service wants to update and keep approval for a form that helps control harmful plant pests and noxious weeds. This affects farmers, gardeners, and businesses dealing with plants, making sure they follow the rules to keep plants safe. They’re asking for more time to collect this info, with no new costs expected, so everyone can keep protecting our green spaces.
Next: 2025-13716 — Proposed Collection; Comment Request; Extension: Form 18-K-Annual Report
The SEC wants to keep using Form 18-K, an annual report that foreign governments with U.S. securities must file. About 37 groups spend around 8 hours each year filling it out, with no extra costs involved. The SEC is asking for public comments by September 22, 2025, to make sure this form stays useful and easy to handle.